Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Jackman

Showing results (11-20 of 53) with videos related to

Pageof 6
Sort By:
JAMA Oncology|July 9, 2016
Prospective Study of Repeated Biopsy Feasibility and Acquired Resistance at Disease Progression in Patients With Advanced EGFR Mutant Lung Cancer Treated With Erlotinib in a Phase 2 TrialAmanda J Redig, Daniel B Costa, Myriam Taibi, et al.
The Oncologist|September 28, 2013
Chemotherapy with Erlotinib or chemotherapy alone in advanced non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitorsSarah B Goldberg, Geoffrey R Oxnard, Subba Digumarthy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 30, 2010
Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinibStephanie Heon, Beow Y Yeap, Gregory J Britt, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 3, 2016
Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIsJessica J Lin, Stephanie Cardarella, Christine A Lydon, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 22, 2013
Tumor volume decrease at 8 weeks is associated with longer survival in EGFR-mutant advanced non-small-cell lung cancer patients treated with EGFR TKIMizuki Nishino, Suzanne E Dahlberg, Stephanie Cardarella, et al.
AJR. American Journal of Roentgenology|June 25, 2013
RECIST 1.1 in NSCLC patients with EGFR mutations treated with EGFR tyrosine kinase inhibitors: comparison with RECIST 1.0Mizuki Nishino, Stephanie Cardarella, David M Jackman, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|June 30, 2012
Tumoral cavitation in patients with non-small-cell lung cancer treated with antiangiogenic therapy using bevacizumabMizuki Nishino, Sarah K Cryer, Yuka Okajima, et al.
The American Journal of Surgical Pathology|July 14, 2012
Pathologic characteristics of NUT midline carcinoma arising in the mediastinumAndrew G Evans, Christopher A French, Michael J Cameron, et al.
Journal of Oncology Practice|June 26, 2018
Implementation to Optimization: A Tailored, Data-Driven Approach to Improve Provider Efficiency and Confidence in Use of the Electronic Medical RecordSarah S Kadish, Erica L Mayer, David M Jackman, et al.
European Journal of Radiology|March 3, 2015
Interstitial lung abnormalities in treatment-naïve advanced non-small-cell lung cancer patients are associated with shorter survivalMizuki Nishino, Stephanie Cardarella, Suzanne E Dahlberg, et al.
Pageof 6

Showing results (11-20 of 53) with videos related to

Sort By:
Pageof 6
JAMA Oncology|July 9, 2016
Prospective Study of Repeated Biopsy Feasibility and Acquired Resistance at Disease Progression in Patients With Advanced EGFR Mutant Lung Cancer Treated With Erlotinib in a Phase 2 TrialAmanda J Redig, Daniel B Costa, Myriam Taibi, et al.
The Oncologist|September 28, 2013
Chemotherapy with Erlotinib or chemotherapy alone in advanced non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitorsSarah B Goldberg, Geoffrey R Oxnard, Subba Digumarthy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 30, 2010
Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinibStephanie Heon, Beow Y Yeap, Gregory J Britt, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 3, 2016
Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIsJessica J Lin, Stephanie Cardarella, Christine A Lydon, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 22, 2013
Tumor volume decrease at 8 weeks is associated with longer survival in EGFR-mutant advanced non-small-cell lung cancer patients treated with EGFR TKIMizuki Nishino, Suzanne E Dahlberg, Stephanie Cardarella, et al.
AJR. American Journal of Roentgenology|June 25, 2013
RECIST 1.1 in NSCLC patients with EGFR mutations treated with EGFR tyrosine kinase inhibitors: comparison with RECIST 1.0Mizuki Nishino, Stephanie Cardarella, David M Jackman, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|June 30, 2012
Tumoral cavitation in patients with non-small-cell lung cancer treated with antiangiogenic therapy using bevacizumabMizuki Nishino, Sarah K Cryer, Yuka Okajima, et al.
The American Journal of Surgical Pathology|July 14, 2012
Pathologic characteristics of NUT midline carcinoma arising in the mediastinumAndrew G Evans, Christopher A French, Michael J Cameron, et al.
Journal of Oncology Practice|June 26, 2018
Implementation to Optimization: A Tailored, Data-Driven Approach to Improve Provider Efficiency and Confidence in Use of the Electronic Medical RecordSarah S Kadish, Erica L Mayer, David M Jackman, et al.
European Journal of Radiology|March 3, 2015
Interstitial lung abnormalities in treatment-naïve advanced non-small-cell lung cancer patients are associated with shorter survivalMizuki Nishino, Stephanie Cardarella, Suzanne E Dahlberg, et al.
Pageof 6